Table 7 Follow-up data (multiple statements were possible)

Re-PCI MB, In-segment (no., percent)

5 (7.9%)

63

4 (11.8%)

34

1.55^a

(0.39; 6.19) 0.54

Re-PCI SB, In-segment (no., percent)

3 (4.8%)

63

3 (8.8%)

34

1.94^a

(0.37; 10.16) 0.44

Definite stent thrombosis ( no., percent)

0 (0%)

63

3 (8.8%)

34

−0.088^b

0.041^c

CABG related to the target lesion (no., percent)

2 (3.2%)

63

0 (0%)

34

0.032^a

0.54

TLR (no., percent)

10 (15.9%)

63

10 (29.4%)

34

2.21^a

(0.81; 6.01) 0.12

PCI target vessel, non-target lesion or CABG not related to target lesion (no., percent)

0 (0%)

63

1 (2.9%)

34

−0.029^b

0.35^c

TVR (no., percent)

10 (15.9%)

63

11 (32.4%)

34

2.53^a

(0. 95; 6.80) 0.07

Cardiac death (no., percent)

5 (7.9%)

63

5 (14.7%)

34

2.00^a

(0.54; 7.47) 0.30

All MACE (no., percent)

15 (23.8%)

63

16 (47.1%)

34

2.84^a

(1.17; 6.92) 0.02

PCI non-target vessel (no., percent)

6 (9.5%)

63

5 (14.7%)

34

1.64^a

(0.46; 5.82) 0.45

Diagnostic cardiac catheterization without PCI (no., percent)

3 (4.8%)

63

2 (5.9%)

34

1.25^a

(0.20; 7.87) 0.81

Non-cardiac death (no., percent)

2 (3.2%)

63

0 (0%)

34

0.032^b

0.54^c

Lost of follow-up (no., percent)

1 (1.6%)

64

0 (0%)

34

−0.016^b

1.00^c

Follow-up duration, months (mean, range, SD)

14.1 (0–41; 13.1)

63

12.3 (1–46; 12.8)

34

1.79^b

(−3.70; 7.27) 0.52